Related Experiment Video

Updated: Aug 17, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce

A McLachlan1, N Kekre, J McNulty

  • 1University of Windsor, Windsor, Ontario, Canada.

Apoptosis : an International Journal on Programmed Cell Death
|May 24, 2005
PubMed

Insights

Pancratistatin (PST), a natural compound, selectively induces apoptosis in cancer cells, sparing normal cells. Mitochondria appear to be PST's target, offering potential for novel cancer therapies.

Area of Science:

  • Natural Product Chemistry
  • Cancer Biology
  • Cellular Pharmacology

Background:

  • Current cancer treatments often lack specificity, affecting normal cells alongside cancerous ones.
  • Natural compounds are being explored for targeted anti-cancer activity, with Taxol as an example.
  • Pancratistatin (PST), isolated from Pancratium littorale, exhibits antineoplastic properties, but its specificity and mechanism are unclear.

Purpose of the Study:

  • To investigate the selective effects of Pancratistatin (PST) on cancerous versus normal cells.
  • To elucidate the cellular mechanism and potential mitochondrial site of action for PST's anti-cancer effects.

Main Methods:

  • Treatment of cancerous and normal cell lines with Pancratistatin (PST).
  • Analysis of cellular responses, including apoptosis induction.
  • Investigation of potential mitochondrial involvement in PST's mechanism of action.

Main Results:

  • Pancratistatin (PST) demonstrated selective induction of apoptosis specifically in cancer cells.
  • Normal cells treated with PST did not exhibit significant signs of apoptosis.
  • Mitochondria are indicated as a potential primary site of action for PST within cancer cells.

Conclusions:

  • Pancratistatin (PST) exhibits cancer-selective apoptosis-inducing activity.
  • The findings suggest mitochondria as a key target for PST in cancer cells.
  • Identifying cancer-specific targets like those of PST could lead to more effective, less toxic cancer therapies.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...